IRIS
GIULIANO, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.578
EU - Europa 3.666
NA - Nord America 3.274
SA - Sud America 616
AF - Africa 108
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.252
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.122
SG - Singapore 2.402
RU - Federazione Russa 1.810
CN - Cina 1.107
IT - Italia 912
BR - Brasile 495
HK - Hong Kong 386
VN - Vietnam 357
DE - Germania 245
NL - Olanda 146
IN - India 112
FI - Finlandia 97
GB - Regno Unito 96
CA - Canada 84
FR - Francia 79
AR - Argentina 57
IE - Irlanda 57
KR - Corea 56
SE - Svezia 44
MX - Messico 43
CI - Costa d'Avorio 42
PL - Polonia 33
ZA - Sudafrica 31
UA - Ucraina 29
ES - Italia 24
AT - Austria 22
BD - Bangladesh 21
BE - Belgio 18
IQ - Iraq 17
JP - Giappone 17
EC - Ecuador 16
PK - Pakistan 15
ID - Indonesia 12
VE - Venezuela 10
CZ - Repubblica Ceca 9
CO - Colombia 8
PY - Paraguay 8
TR - Turchia 8
UZ - Uzbekistan 8
CL - Cile 7
MA - Marocco 7
AE - Emirati Arabi Uniti 6
MY - Malesia 6
PE - Perù 6
IR - Iran 5
LT - Lituania 5
PS - Palestinian Territory 5
RS - Serbia 5
UY - Uruguay 5
AU - Australia 4
DZ - Algeria 4
IL - Israele 4
AL - Albania 3
BW - Botswana 3
BY - Bielorussia 3
BZ - Belize 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
HN - Honduras 3
JM - Giamaica 3
KZ - Kazakistan 3
MN - Mongolia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
PA - Panama 3
PH - Filippine 3
SA - Arabia Saudita 3
AM - Armenia 2
BB - Barbados 2
BF - Burkina Faso 2
BG - Bulgaria 2
BO - Bolivia 2
BS - Bahamas 2
CH - Svizzera 2
CR - Costa Rica 2
EG - Egitto 2
GR - Grecia 2
GT - Guatemala 2
HR - Croazia 2
IS - Islanda 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
MD - Moldavia 2
MG - Madagascar 2
MK - Macedonia 2
NG - Nigeria 2
NO - Norvegia 2
PT - Portogallo 2
SD - Sudan 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AZ - Azerbaigian 1
BH - Bahrain 1
ET - Etiopia 1
EU - Europa 1
Totale 12.230
Salva come PNG Salva come JPEG
Città #
Singapore 1.126
Moscow 450
Chandler 421
Hong Kong 385
Hefei 349
Beijing 324
Ashburn 286
Naples 200
Santa Clara 196
Napoli 127
Amsterdam 123
Dallas 116
Millbury 112
Ho Chi Minh City 108
Los Angeles 106
Munich 93
Hanoi 66
Buffalo 64
New York 63
Kochi 54
Princeton 54
Seoul 54
Des Moines 52
Redondo Beach 49
São Paulo 47
Turku 43
Boston 41
Nanjing 39
The Dalles 38
Wilmington 37
Dong Ket 36
Lawrence 34
Seattle 28
Pune 26
Ottawa 25
Warsaw 25
Milan 24
Montreal 24
Nuremberg 24
Rome 24
Mexico City 23
Frankfurt am Main 22
Orem 22
Toronto 21
Denver 20
Stockholm 20
Poplar 19
London 18
Rio de Janeiro 18
Brooklyn 17
Haiphong 17
Jacksonville 17
Chicago 15
Houston 15
Tokyo 15
Johannesburg 14
Belo Horizonte 13
Casoria 13
Da Nang 13
Formia 13
Pomigliano d'Arco 13
Tianjin 13
Biên Hòa 12
Boardman 12
Brussels 12
Dearborn 11
Helsinki 11
Nanchang 11
Vienna 11
Atlanta 10
Falkenstein 10
Ninh Bình 10
Porto Alegre 10
Shenyang 10
Woodbridge 10
Changsha 9
Hải Dương 9
Jiaxing 9
Manchester 9
Villaricca 9
Caserta 8
Charlotte 8
Chennai 8
Guangzhou 8
Hebei 8
Lauterbourg 8
Phoenix 8
Redwood City 8
Shanghai 8
Baghdad 7
Bologna 7
Brasília 7
Curitiba 7
Dublin 7
Fairfield 7
Genoa 7
Guayaquil 7
Kronberg 7
Salerno 7
Salvador 7
Totale 6.198
Salva come PNG Salva come JPEG
Nome #
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 157
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 150
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 147
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 144
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 144
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 139
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 138
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? 133
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 131
Prevalence of Sarcopenia in Women with Breast Cancer 130
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction 126
Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review 124
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype 123
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 122
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 121
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 121
R0 surgical resection of giant dedifferentiated retroperitoneal liposarcomas in the COVID era with and without nephrectomy: A case report 120
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 119
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 118
Extraskeletal Ewing's sarcoma of the mediastinum: Case report 117
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 117
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 117
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 117
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 116
Tumor characteristics and prognosis in familial breast cancer 115
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 115
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 115
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 114
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations 113
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 112
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis 112
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 112
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 112
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 112
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 112
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 111
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 110
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 110
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 109
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 108
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 108
Mechanisms of lapatinib resistance in HER2-driven breast cancer 107
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 107
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 106
Biological mechanisms and clinical implications of endocrine resistance in breast cancer. 104
Circulating tumor cells in newly diagnosed inflammatory breast cancer 104
Tumori maligni del colon 104
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 104
Serum biomarkers of inflammation and vascular damage upon SARS-Cov-2 mRNA vaccine in patients with thymic epithelial tumors 103
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 103
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study 103
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 102
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. 102
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. 102
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy 102
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 101
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis 101
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance 101
A djuvant treatment in patients at high risk of recurrence of thymoma: Efficacy and safety of a three-dimensional conformal radiation therapy regimen 101
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 100
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 100
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 100
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients 99
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. 99
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. 99
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase 99
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type 98
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. 98
Boosting the immune response with the combination of electrochemotherapy and immunotherapy: A new weapon for squamous cell carcinoma of the head and neck? 98
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. 97
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 96
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 96
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis 96
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 96
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? 96
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) 94
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 94
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives 94
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 93
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. 93
Epigenetic control of gene expression: Potential implications for cancer treatment 92
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. 91
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 91
Crosslink between atrial fibrillation and cancer: a therapeutic conundrum 90
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 89
Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes 88
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome 87
Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions 87
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 87
Immunological signature of patients with thymic epithelial tumors and Good syndrome 86
Ribociclib in newly diagnosed hepatitis B infection: A case report 85
Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report 85
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 84
Genetics and management of locally advanced carcinomas of the head and neck: Role of altered fractionation radiotherapy 84
Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study 82
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 82
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 82
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy 80
Optimal multidisciplinary treatment of oral cavity mucosal melanoma: Outcome analysis in a case series 79
Die and let live: harnessing BikDD to combat breast cancer stem cells. 77
Totale 10.591
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.816
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.816
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021190 0 0 0 0 0 18 28 13 49 17 20 45
2021/2022593 9 4 17 9 5 23 14 23 67 59 154 209
2022/2023993 96 89 37 63 125 103 18 94 146 147 51 24
2023/2024782 33 120 92 51 42 102 11 75 23 24 130 79
2024/20254.185 167 175 14 103 125 224 416 240 344 484 1.554 339
2025/20264.988 886 665 958 829 1.336 314 0 0 0 0 0 0
Totale 12.522